Reify Health, a Boston, MA-based provider of cloud-based solutions that connect and empower the clinical trial ecosystem, raised $30m in Series B funding.
The round was led by Battery Ventures with participation from previous investors including Sierra Ventures and Asset Management Ventures.
The company intends to use the funds to expand its StudyTeam enrollment solution and accelerate additional platform solutions.
Led by Ralph Passarella, CEO and co-founder, and Michael Lin, co-founder and executive chairman, Reify provides StudyTeam, which allows healthcare staff at clinical research sites to upgrade the systems they depend on to run trials. By bringing them onto a shared platform with biopharma sponsors, Reify enables industry players to accelerate clinical trial enrollment and reduce workloads for stakeholders across the ecosystem. StudyTeam systematically eliminates redundant work across the clinical trial process while generating novel insights that speed up trials. The platform is used by 1,800 research sites across 26 countries and by half of the top-20 global biopharma companies, including Eli Lilly and Company and Amgen.
FinSMEs
12/08/2020